SCHEMBL9819481

SCHEMBL9819481

COC(=O)Nc1cccc(Cl)c1Cl

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.62
MEN1 O00255 9/20 0.62
MAPK1 P28482 2/20 0.58
MAPT P10636 5/20 0.56
LMNA P02545 4/20 0.56
PDK1 Q15118 1/20 0.54
PDK2 Q15119 1/20 0.54
PDK3 Q15120 1/20 0.54
PDK4 Q16654 1/20 0.54
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 3/20 0.54
HPGD P15428 2/20 0.54
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
POLB P06746 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3783627 0.90 GPR35 (0.57) KMT2AMEN1MAPK1MAPTLMNA
SCHEMBL513878 0.85 MEN1 (0.58) KMT2AMEN1LMNAPDK1PDK2
SCHEMBL2091197 0.84 ALDH1A1 (0.73) MAPK1MAPTLMNAALDH1A1KDM4E
SCHEMBL3793403 0.84 NLRP3 (0.53) KMT2AMEN1MAPTPDK1PDK2
SCHEMBL3803167 0.83 ALDH1A1 (0.77) KMT2AMEN1MAPK1MAPTLMNA
SCHEMBL2093882 0.82 RAF1 (0.53) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL3612815 0.81 MEN1 (0.67) KMT2AMEN1MAPK1MAPTLMNA
SCHEMBL30623497 0.81 MEN1 (0.67) KMT2AMEN1MAPK1MAPTLMNA
SCHEMBL10710090 0.80 MEN1 (0.79) KMT2AMEN1MAPK1MAPTLMNA
SCHEMBL2093283 0.80 NLRP3 (0.60) KMT2AMEN1MAPTLMNAPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221515-A1 MONOSACCHARIDE DERIVATIVES RANBAXY LABORATORIES INC. (IN) 2009-09-03 US disclosed
US-20090221515-A1 MONOSACCHARIDE DERIVATIVES RANBAXY LABORATORIES INC. (IN) 2009-09-03 US disclosed
EP-0162669-B1 ANTICONVULSIVE COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-12-11 EP disclosed
US-4588729-A Treating convulsions with dihydrouracil derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1986-05-13 US disclosed
EP-0162669-A2 Anticonvulsive compounds KYOWA HAKKO KOGYO CO., LTD. (JP) 1985-11-27 EP disclosed
US-4138422-A UREAS AND CARBAMATES FROM ISOCYANATES ON AN INERT SOLID GRANULAR MATERIAL UNION CARBIDE CORPORATION (US) 1979-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221515-A1 MONOSACCHARIDE DERIVATIVES HLA-DRB1, MUC1, FUT5 KMT2A 3928/4885MEN1 1520/4885MAPK1 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.